Jackie Syrop


Shift in Site of Care for Oncology Has Affected the Marketplace for Oncology Drugs

December 15, 2017

Hospitals classified as 340B institutions are playing an increasingly large role in oncology care, and the rapid growth in the federal 340B program has resulted in big changes in the oncology drug marketplace, according to a recent white paper released by the Community Oncology Alliance.

Measuring Antibodies to Infliximab To Guide Treatment Intensification in Crohn Disease

December 14, 2017

A significant proportion of patients with Crohn disease (CD) who initially respond to infliximab therapy experience secondary loss of response with symptom flares. Treatment intensification (using increases in dose, dose frequency, or a combination of both to implement intensification) is a suggested strategy for regaining response.

PhRMA Sues California Over State's New Drug Pricing Law

December 12, 2017

The pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) sued California state officials in federal court on December 8, 2017, over California’s new drug pricing law, which the group states is “unprecedented and unconstitutional.”

Phase 1 Data Show Sandoz's Proposed Pegfilgrastim Biosimilar Matches Neulasta's Profile

December 09, 2017

Results from a phase 1 clinical trial show that Sandoz’s proposed pegfilgrastim biosimilar (LA-EP2006) matched the reference biologic, Amgen’s Neulasta, in terms of safety, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy subjects.

Study Finds Switching Patients to Biosimilar Infliximab Safe and Effective in IBD

December 07, 2017

No differences in drug levels or disease activity were found when adult patients with inflammatory bowel disease (IBD) were switched from originator infliximab (Remicade) to a biosimilar infliximab (Inflectra) as part of routine care, according to the results of a Dutch study.

NAS Report: Consumer Access to Affordable Medicines Is a Public Health Imperative

December 07, 2017

A new report from calls for big changes in how US pharmaceuticals are priced, promoted, and sold so that treatments are more affordable and equally available to all Americans, as market mechanisms that would usually moderate prices have been blunted or eliminated.

Can Modeling and Simulation Drive Clinical Development of Biosimilars?

December 05, 2017

The failure rate of biosimilars in clinical trials is considered high because of the complex manufacturing process and the high variability expected for biologics. With associated development costs for a biosimilar estimated to be $100 million, there is a high risk-cost relationship in the establishing clinical biosimilarity.

CVS Health Agrees to Buy Aetna, Possibly Reshaping US Healthcare

December 04, 2017

CVS Health has agreed to purchase Aetna, a transaction that would combine CVS’s retail pharmacies with Aetna’s health insurance company in a $69 billion deal that could create a company with annual revenue of $240 billion, and that has the potential to reshape the US healthcare system.

Humira Competitor Tremfya Gains European Approval for Psoriasis Treatment

November 28, 2017

Janssen-Cilag International’s biologic drug guselkumab (Tremfya) has received approval from the European Commission (EC) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.